HK1129315A1 - Method of treating hepatitis c patients - Google Patents

Method of treating hepatitis c patients

Info

Publication number
HK1129315A1
HK1129315A1 HK09108390.0A HK09108390A HK1129315A1 HK 1129315 A1 HK1129315 A1 HK 1129315A1 HK 09108390 A HK09108390 A HK 09108390A HK 1129315 A1 HK1129315 A1 HK 1129315A1
Authority
HK
Hong Kong
Prior art keywords
patients
treating hepatitis
hepatitis
relapsed
infection
Prior art date
Application number
HK09108390.0A
Other languages
English (en)
Inventor
Janice K Albrecht
Clifford A Brass
Robert Orville Ii Ralston
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40262964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1129315(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1129315A1 publication Critical patent/HK1129315A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
HK09108390.0A 2007-09-14 2009-09-14 Method of treating hepatitis c patients HK1129315A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99375307P 2007-09-14 2007-09-14
US99876207P 2007-10-12 2007-10-12
US149407P 2007-10-30 2007-10-30
PCT/US2008/010626 WO2009038663A1 (en) 2007-09-14 2008-09-11 Method of treating hepatitis c patients

Publications (1)

Publication Number Publication Date
HK1129315A1 true HK1129315A1 (en) 2009-11-27

Family

ID=40262964

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09108390.0A HK1129315A1 (en) 2007-09-14 2009-09-14 Method of treating hepatitis c patients

Country Status (18)

Country Link
US (1) US20100226885A1 (xx)
EP (2) EP2061513B1 (xx)
JP (1) JP2010539165A (xx)
CN (1) CN101883590A (xx)
AT (1) ATE519503T1 (xx)
AU (1) AU2008301981A1 (xx)
CA (1) CA2699280A1 (xx)
CY (1) CY1112116T1 (xx)
DK (1) DK2061513T3 (xx)
ES (1) ES2369321T3 (xx)
HK (1) HK1129315A1 (xx)
HR (1) HRP20110637T1 (xx)
MX (1) MX2010002909A (xx)
NZ (1) NZ583825A (xx)
PL (1) PL2061513T3 (xx)
PT (1) PT2061513E (xx)
SI (1) SI2061513T1 (xx)
WO (1) WO2009038663A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
CA2833887A1 (en) * 2011-05-04 2012-11-08 Merck Sharp & Dohme Corp. Drug substances, pharmaceutical compositions and methods for preparing the same
ME03009B (me) 2011-09-16 2018-10-20 Gilead Pharmasset Llc Metode za lecenje hcv-a
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
BR112014010295A2 (pt) 2011-10-31 2017-04-18 Gilead Pharmassett Llc métodos e composições para o tratamento de vírus de hepatite c
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
MD4430C1 (ro) 2011-11-29 2017-03-31 Gilead Pharmasset Llc Compoziţii şi metode de tratament al hepatitei virale C
US20140363396A1 (en) 2012-02-01 2014-12-11 Kadmon Pharmaceuticals Llc Once daily treatment of hepatitis c with ribavirin and taribavirin
EA029081B9 (ru) 2013-01-31 2018-09-28 Джилид Фармассет Ллс Комбинированный состав двух противовирусных соединений
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
CA2354536A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
JP2000256211A (ja) * 1999-03-02 2000-09-19 Schering Plough Corp Ｈｉｖ治療薬
BR0112540A (pt) 2000-07-21 2003-06-24 Schering Corp Peptìdios como inibidores da ns-3-serina protease do vìrus da hepatite c
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CA2557495C (en) * 2004-02-27 2014-04-15 Schering Corporation Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2006016930A2 (en) * 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
US20070004635A1 (en) * 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
AR059429A1 (es) * 2006-02-09 2008-04-09 Schering Corp Combinaciones que involucran el (los) inhibidor(es) de la protesa hcv y metodos de tratamiento relacionados al (los) mismo (s)
WO2009150194A1 (en) * 2008-06-10 2009-12-17 Janssen Pharmaceutica Nv Telaprevir dosing regimen

Also Published As

Publication number Publication date
ATE519503T1 (de) 2011-08-15
ES2369321T3 (es) 2011-11-29
PT2061513E (pt) 2011-10-17
HRP20110637T1 (hr) 2011-10-31
DK2061513T3 (da) 2011-11-21
EP2061513A1 (en) 2009-05-27
CY1112116T1 (el) 2015-11-04
CA2699280A1 (en) 2009-03-26
MX2010002909A (es) 2010-03-30
SI2061513T1 (sl) 2011-11-30
PL2061513T3 (pl) 2011-12-30
WO2009038663A1 (en) 2009-03-26
JP2010539165A (ja) 2010-12-16
AU2008301981A1 (en) 2009-03-26
CN101883590A (zh) 2010-11-10
NZ583825A (en) 2012-06-29
US20100226885A1 (en) 2010-09-09
EP2489369A1 (en) 2012-08-22
EP2061513B1 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
HK1129315A1 (en) Method of treating hepatitis c patients
HK1142270A1 (en) Silibinin component for the treatment of hepatitis
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
MY144318A (en) Methods of treating hiv infection.
SG150559A1 (en) Antineoplastic combinations of cci-779 and rituximab
MX2010003916A (es) Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih).
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
EP1742675A4 (en) TREATMENT OF BIOMEDICAL WASTE
HK1096320A1 (en) Apheresis device
PL1799231T3 (pl) Zastosowanie cyklodekstryny do leczenia i zapobiegania chorobom zapalnym oskrzeli
UA88655C2 (ru) S-миртазапин для лечения прилива крови
EP2224943A4 (en) USE OF A HUMAN ANTIBODY TO NEUTRALIZE HEPATITIS B VIRUS FOR THE PREVENTION OR TREATMENT OF HEPATITIS B INFECTIONS
PL383722A1 (pl) Sposoby i materiały z trans-klomifenem do leczenia bezpłodności u mężczyzn
BRPI0417108A (pt) métodos de tratamento de rejeições de transplantes em pacientes
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
WO2009033183A3 (en) Compounds and methods for treatment of hcv and conditions associated with cd81 binding
GB2441094B (en) Methods for treatment and prevention of infection
UA90477C2 (ru) Способ лечения гепатита с (варианты)
GB0415181D0 (en) Compounds for use in the treatment of infection
IL187160A0 (en) Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
MY166063A (en) Intravenous antiviral treatments
EP1807108A4 (en) METHOD FOR TREATING AND PREVENTING DISEASES OF BIOLOGICAL LINES
FI20085282A0 (fi) Biotekninen prosessi rautaa sisältävien mineraalien, konsentraattien, steriilien prosessivesien ja yhdisteiden käsittelemiseksi
AU311512S (en) Blood or plasma treatment apparatus

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150911